Akwahosan ho nsɛm a ɛfa ahurututu mu kokoram ho no kyerɛ nsakrae a ɛba nipadua mu nneɛma mu bere a ahurututu mu kokoram nya nkɔanim no.
Mframa mu kokoram yɛ yare a ɛyɛ den a efi nkwammoaa a enni ahoɔden a enyin na ɛkyekyɛ wɔ ahurututu mu.
Saa nkwammoaa yi betumi ama obi anya kokoram na atrɛw akɔ nipadua no afã foforo, na ɛde ɔhaw ahorow ba.
Akwahosan ho nsɛm a ɛfa ahrawa mu kokoram ho no fa nneɛma pii ho, a nea ɛka ho bi ne awosu mu nsakrae, nneɛma a atwa yɛn ho ahyia, ne sɛnea yɛbɔ yɛn bra.
Awosu mu nsakrae betumi aba wɔ DNA a ɛwɔ ahurututu mu nkwammoaa mu no mu, na ama nkwammoaa no anyin na wɔakyekyɛ wɔn ho a wontumi nyɛ ho hwee.
Wobetumi anya saa nsakrae yi afi awo mu anaa obi anya bi, na ebetumi aba sɛ nneɛma bi te sɛ tawa wusiw, radon, asbestos, ne mframa a asɛe na ɛde ba.
Wɔtumi kyekyɛ ahrawa mu kokoram mu ayɛ no akuw mmienu: nkwammoaa nketewa a ɛwɔ ahrawa mu (SCLC) ne nkwammoaa nketewa a enni ahrawa mu (NSCLC).
Akwahosan ho nsɛm a ɛwɔ saa ahurututu mu kokoram yi mu betumi ayɛ soronko, efisɛ wonya awosu mu nsakrae ahorow na wonya ayaresa ho mmuae soronko.
Akwahosan ho nsɛm a ɛfa ahurututu mu kokoram ho no fa sɛnea kokoram nkwammoaa ne nneɛma a atwa ho ahyia, a nipadua mu nkwaadɔm ka ho, di dwuma ho.
Kokoram nkwammoaa tumi twe wɔn ho fi nipadua mu nkwaadɔm a ɛko tia nyarewa no ho, na ɛma wotumi nyin na wɔtrɛw a wɔnhwɛ wɔn.
Bio nso, kokoram mmoawa no nya baabi a wɔtetew a ɛma wɔnyini.
Akwahosan ho nhwehwɛmu a wɔyɛ wɔ ahurututu mu kokoram mu no yɛ ade a ɛyɛ den na ɛyɛ adwuma ntɛmntɛm, na nhwehwɛmufo reyɛ adwuma bere nyinaa sɛnea ɛbɛyɛ a wɔbɛte ɔkwan a wɔfa so sa yare no ase yiye na ama wɔanya ayaresa a etu mpɔn na ama ayarefo no ho atɔ wɔn.
Li Z, Qian Y, Li W, Liu L, Yu L, Liu X, Wu G, Wang Y, Luo W, Fang F, Liu Y, Song F, Cai Z, Chen W, Huang W: Human Lung Adenocarcinoma-Derived Organoid Models for Drug Screening. iScience. 2020, 23 (8): 101411.
Nurwidya F, Syahruddin E, Yunus F: Pain management in lung cancer. Adv Respir Med. 2016, 84 (6): 331-336.
Khan KA, Kennedy MP, Moore E, Crush L, Prendeville S, Maher MM, Burke L, Henry MT: Radiological characteristics, histological features and clinical outcomes of lung cancer patients with coexistent idiopathic pulmonary fibrosis. Lung. 2015, 193 (1): 71-7.
Paramanantham A, Asfiya R, Das S, McCully G, Srivastava A: Extracellular Vesicle (EVs) Associated Non-Coding RNAs in Lung Cancer and Therapeutics. Int J Mol Sci. 2022, 23 (21): .
Lee D, Kim Y, Chung C: Scientific Validation and Clinical Application of Lung Cancer Organoids. Cells. 2021, 10 (11): .
Mucchietto V, Crespi A, Fasoli F, Clementi F, Gotti C: Neuronal Acetylcholine Nicotinic Receptors as New Targets for Lung Cancer Treatment. Curr Pharm Des. 2016, 22 (14): 2160-9.
['Nsɛm a Ɛnsɛ sɛ Wɔka:']
['Wɔayɛ wɛbsaet yi sɛ wɔmfa nkyerɛkyerɛ na wɔmfa nkyerɛkyerɛ afoforo, na ɛnyɛ sɛ wɔde rema aduruyɛ ho afotu anaa wɔde rema adwuma.']
['Ɛnsɛ sɛ wɔde nsɛm a wɔde ama no di dwuma de hwehwɛ yare bi ho yare anaa wɔde sa yare, na ɛsɛ sɛ wɔn a wɔrehwehwɛ ayaresa ho afotu no kohu oduruyɛfo a ɔwɔ tumi krataa.']
['Yɛsrɛ wo hyɛ no nsow sɛ, sɛnea wɔhwɛ nsɛmmisa no so no, sɛ ɛba sɛ wɔrekyerɛw nnipa dodow a wɔanya yare bi ho asɛm a, ɛntaa nsi yiye.']
['Hwehwɛ afotu fi wo duruyɛfo anaa ɔyaresafo foforo a ɔfata hɔ bere biara wɔ yare bi ho. Nnya adwene sɛ wo nsa bɛka oduruyɛfo afotu anaasɛ wubetwa so esiane biribi a woakenkan wɔ wɛbsaet yi so nti. Sɛ wususuw sɛ ebia wo ho behia wo wɔ ayaresa mu a, frɛ 911 anaa kɔ ayaresabea a ɛbɛn wo paa ntɛm ara.']
['Nsɛm a wɔmmɔ ho ban:']
['Digital Millennium Copyright Act a wɔhyɛe wɔ afe 1998 mu, 17 U.S.C. § 512 (DMCA) no ma wɔn a wɔwɔ hokwan sɛ wɔyɛ wɔn nneɛma no kwan sɛ wɔyɛ nea wɔpɛ biara.']
["Sɛ wugye di sɛ nsɛm anaa nneɛma a ɛwɔ yɛn wɛbsaet anaa yɛn dwumadibea no mu bi to wo mmara a wode bɔɔ nneɛma ho ban no a, wo (anaa w'ananmusifo) betumi de krataa akɔma yɛn de aka sɛ yɛnyi nsɛm anaa nneɛma no, anaa yɛmmɔ kwan mma wonnya bi."]
["Ɛsɛ sɛ wɔde krataa ne email na ɛbɔ amanneɛ (hwɛ 'Contact' afã hɔ na wubehu email address)."]
['DMCA hwehwɛ sɛ wo amanneɛbɔ a ɛfa nea wɔkyerɛ sɛ ɛyɛ mmara a wobu so ho no de nsɛm a edidi so yi ka ho: (1) adwuma a mmara bɔ ho ban a wɔkyerɛ sɛ wɔadi so no ho asɛm; (2) nsɛm a wɔkyerɛ sɛ wɔadi so no ho asɛm ne nsɛm a ɛbɛboa yɛn ma yɛahu baabi a ɛwɔ; (3) wo ho nsɛm a yɛde bedi nkitaho, a wo address, telefon nɔma ne email address ka ho; (4) wo nsɛm a ɛkyerɛ sɛ wugye di sɛ nea wɔabɔ ho sobo no nyɛ nea mmara ma ho kwan; ']
['(5) wo nsahyɛ a ɛkyerɛ sɛ nsɛm a ɛwɔ amanneɛbɔ no mu yɛ nokware, na wowɔ tumi sɛ wode nea wɔkyerɛ sɛ woadi ho dwuma no bedi dwuma; ']
['ne (6) nea ɔwɔ tumi sɛ ɔyɛ biribi ma obi a ɔwɔ tumi sɛ ɔyɛ biribi ma no no nsaano nkyerɛwee.']
['Sɛ woamfa nsɛm a yɛaka yi nyinaa anka ho a, ebetumi ama wo ka no akyɛ.']
['Nkitahodi']
['Yɛsrɛ wo, fa nsɛmmisa anaa nyansahyɛ biara a wowɔ brɛ yɛn wɔ e-mail so.']
What is pathophysiology of lung cancer?
The pathophysiology of lung cancer refers to the changes in the normal physiological processes and mechanisms that occur in the development and progression of lung cancer.
Lung cancer is a complex disease that arises from the uncontrolled growth and division of abnormal cells in the lungs.
These cells can form tumors and spread to other parts of the body, leading to various symptoms and complications.
The pathophysiology of lung cancer involves several factors, including genetic mutations, environmental factors, and lifestyle choices.
Genetic mutations can occur in the DNA of lung cells, leading to uncontrolled cell growth and division.
These mutations can be inherited or acquired, and they can be caused by exposure to carcinogens, such as tobacco smoke, radon, asbestos, and air pollution.
Lung cancer can be classified into two main types: small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). NSCLC is further divided into three subtypes: adenocarcinoma, squamous cell carcinoma, and large cell carcinoma.
The pathophysiology of these types of lung cancer can differ, as they have different genetic mutations and respond differently to treatment.
The pathophysiology of lung cancer also involves the interaction between cancer cells and the surrounding tissue, including the immune system.
Cancer cells can evade the immune system, allowing them to grow and spread unchecked.
Additionally, the tumor microenvironment can promote tumor growth and metastasis by providing a supportive environment for cancer cells.
The pathophysiology of lung cancer is a complex and dynamic process, and researchers are continuously working to better understand the underlying mechanisms to develop more effective treatments and improve patient outcomes.
Disclaimer: medical
This web site is provided for educational and informational purposes only and does not constitute providing medical advice or professional services.
The information provided should not be used for diagnosing or treating a health problem or disease, and those seeking personal medical advice should consult with a licensed physician.
Please note the neural net that generates answers to the questions, is specially inaccurate when it comes to numeric content. For example, the number of people diagnosed with a specific disease.
Always seek the advice of your doctor or other qualified health provider regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. If you think you may have a medical emergency, call 911 or go to the nearest emergency room immediately. No physician-patient relationship is created by this web site or its use. Neither BioMedLib nor its employees, nor any contributor to this web site, makes any representations, express or implied, with respect to the information provided herein or to its use.
Disclaimer: copyright
The Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (the “DMCA”) provides recourse for copyright owners who believe that material appearing on the Internet infringes their rights under U.S. copyright law. If you believe in good faith that any content or material made available in connection with our website or services infringes your copyright, you (or your agent) may send us a notice requesting that the content or material be removed, or access to it blocked. Notices must be sent in writing by email (see 'Contact' section for email address) . The DMCA requires that your notice of alleged copyright infringement include the following information: (1) description of the copyrighted work that is the subject of claimed infringement; (2) description of the alleged infringing content and information sufficient to permit us to locate the content; (3) contact information for you, including your address, telephone number and email address; (4) a statement by you that you have a good faith belief that the content in the manner complained of is not authorized by the copyright owner, or its agent, or by the operation of any law; (5) a statement by you, signed under penalty of perjury, that the information in the notification is accurate and that you have the authority to enforce the copyrights that are claimed to be infringed; and (6) a physical or electronic signature of the copyright owner or a person authorized to act on the copyright owner’s behalf. Failure to include all of the above information may result in the delay of the processing of your complaint.
['Ɛfa ho']
['BioMedLib de kɔmputa a wɔde di dwuma (mfidie a wɔde sua ade) na ɛma nsɛmmisa ne mmuae.']
['Yɛde nhoma ahorow a ɛfa nnuruyɛ mu ɔpepem 35 a ɛwɔ PubMed/Medline ne RefinedWeb mu na efii ase.']
